Progyny (PGNY) Expected to Announce Earnings on Thursday

Progyny (NASDAQ:PGNY) is projected to issue its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect the company to announce earnings of $0.3350 per share and revenue of $348.6260 million for the quarter. Progyny has set its FY 2026 guidance at 1.980-2.09 EPS and its Q2 2026 guidance at 0.500-0.53 EPS. Interested persons may visit the the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:45 PM ET.

Progyny (NASDAQ:PGNY) last posted its quarterly earnings data on Thursday, May 7th. The company reported $0.50 EPS for the quarter, topping analysts’ consensus estimates of $0.26 by $0.24. Progyny had a return on equity of 13.34% and a net margin of 5.23%.The company had revenue of $328.50 million for the quarter, compared to the consensus estimate of $326.46 million. During the same quarter in the previous year, the business earned $0.17 EPS. The company’s quarterly revenue was down 26.4% compared to the same quarter last year. On average, analysts expect Progyny to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Progyny Price Performance

PGNY stock opened at $31.37 on Thursday. The firm has a market cap of $2.46 billion, a PE ratio of 40.74, a P/E/G ratio of 2.44 and a beta of 1.01. Progyny has a 12 month low of $16.10 and a 12 month high of $33.06. The firm has a 50 day simple moving average of $28.29 and a 200 day simple moving average of $23.17.

Progyny declared that its board has initiated a stock buyback program on Tuesday, May 26th that allows the company to repurchase $200.00 million in outstanding shares. This repurchase authorization allows the company to reacquire up to 10.3% of its stock through open market purchases. Stock repurchase programs are typically an indication that the company’s board believes its stock is undervalued.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the company. Citigroup reiterated an “outperform” rating on shares of Progyny in a research report on Monday, May 11th. Truist Financial lifted their target price on Progyny from $30.00 to $33.00 and gave the stock a “buy” rating in a report on Monday, June 22nd. Barclays reaffirmed an “equal weight” rating and set a $34.00 target price (up from $27.00) on shares of Progyny in a research report on Tuesday. Bank of America upped their target price on Progyny from $29.00 to $31.00 and gave the company a “buy” rating in a report on Tuesday, June 2nd. Finally, BTIG Research increased their price target on Progyny from $30.00 to $40.00 and gave the company a “buy” rating in a research report on Friday, July 24th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Progyny has a consensus rating of “Moderate Buy” and an average price target of $33.25.

Insiders Place Their Bets

In related news, EVP Allison Swartz sold 1,199 shares of the company’s stock in a transaction that occurred on Wednesday, June 3rd. The shares were sold at an average price of $25.02, for a total value of $29,998.98. Following the completion of the sale, the executive vice president owned 83,316 shares in the company, valued at approximately $2,084,566.32. This represents a 1.42% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Cheryl Scott sold 7,439 shares of the firm’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $26.39, for a total transaction of $196,315.21. Following the completion of the transaction, the director directly owned 19,772 shares of the company’s stock, valued at $521,783.08. This represents a 27.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 36,916 shares of company stock worth $939,875 in the last quarter. Corporate insiders own 9.90% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. State Street Corp lifted its stake in Progyny by 1.5% in the 4th quarter. State Street Corp now owns 2,953,186 shares of the company’s stock worth $75,838,000 after acquiring an additional 44,642 shares in the last quarter. Wellington Management Group LLP grew its stake in Progyny by 260.9% during the 4th quarter. Wellington Management Group LLP now owns 2,243,268 shares of the company’s stock valued at $57,607,000 after acquiring an additional 1,621,688 shares in the last quarter. Ameriprise Financial Inc. grew its stake in Progyny by 37.6% during the 2nd quarter. Ameriprise Financial Inc. now owns 1,996,957 shares of the company’s stock valued at $43,933,000 after acquiring an additional 545,431 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Progyny by 1.1% in the 4th quarter. Geode Capital Management LLC now owns 1,972,219 shares of the company’s stock valued at $50,655,000 after purchasing an additional 20,533 shares during the period. Finally, Dimensional Fund Advisors LP increased its holdings in shares of Progyny by 12.1% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,712,039 shares of the company’s stock valued at $43,966,000 after purchasing an additional 184,679 shares during the period. 94.93% of the stock is owned by institutional investors and hedge funds.

About Progyny

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.